BRIEF-Delmar Pharmaceuticals provides VAL-083 updates from ongoing American Association For Cancer Research annual meeting
April 5 Delmar Pharmaceuticals Inc:
* Delmar pharmaceuticals provides val-083 updates from the ongoing American Association For Cancer Research (AACR) annual meeting
* Delmar Pharmaceuticals Inc - VAL-083 is active in cells with t790m and KRAS mutations indicating that agent can overcome TKI-resistance
* Delmar Pharma- poster demonstrates that val-083 has differentiated moa with a dual signaling pathway to cause permanent DNA damage in NSCLC cell lines Source text for Eikon: Further company coverage: